Latest news with #antiobesitydrugs
Medscape
13 hours ago
- Health
- Medscape
ACC Revises Obesity Control Strategies in Heart Failure
A new Scientific Statement from the American College of Cardiology (ACC) has named two anti-obesity drugs as options for symptom control in patients with heart failure. The benefit for these incretin mimics, semaglutide and tirzepatide, is attributed to symptom control, according to the statement. The document, published on June 13 in the Journal of the American College of Cardiology , states that each medication has the potential to reduce cardiovascular (CV) events related to heart failure, but neither has yet done so on the basis of level 1 evidence. The new recommendation appl ies only to heart failure with preserved ejection fraction (HFpEF). The safety and efficacy of these drugs has yet to be established for heart failure with reduced ejection fraction (HFrEF), according to the ACC statement. The new anti-obesity drugs were approved initially for type 2 diabetes. On the basis of substantial weight loss and their relative safety, the FDA subsequently granted indications for obesity alone in patients with at least one additional obesity-related comorbidity, such as hypertension, dyslipidemia, or obstructive sleep apnea. Current Indications for Incretin Mimetics Semaglutide has an indication for patients with CV disease, but not heart failure specifically, and obesity on the basis of the 2023 SELECT trial. Tirzepatide has an indication for patients with sleep apnea and obesity in the absence of diabetes on the basis of the 2024 SURMOUNT-OSA trial. In the 2023 STEP-HFpEF trial with semaglutide and the 2025 SUMMIT trial with tirzepatide, each agent was associated with a reduction in symptoms of heart failure in patients with HFpEF. However, the study designs and outcomes differed. For one, the HFpEF entry criterion was a left ventricular ejection fraction ≥ 45% in STEP-HFpEF but ≥ 50% in the SUMMIT trial. In dual primary endpoints, both included changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ), but the first of the two trials evaluated weight change, while the second evaluated a composite endpoint of CV death and heart failure-related events. By listing semaglutide and tirzepatide as options within a comprehensive review of the treatment of obesity in heart failure, the new document steps in front of current regulatory guidance. In a table that juxtaposed FDA-approved indications for these drugs to evidence-based benefits as defined by the statement, only the latter identifies a role in heart failure. 'The intent of the Writing Committee in including this table was to highlight that there are no FDA-approved heart failure indications for the use of incretin-based anti-obesity medications to date,' said Michelle M. Kittleson, MD, PhD, director of Heart Failure Research at Cedars-Sinai Medical Center in Los Angeles, who chaired the committee. 'While clinicians might identify individuals with heart failure who meet the standard FDA-approved indications, it is important to also identify which of those patients also meet inclusion criteria for th e heart failure trials were benefit was shown,' Kittleson said. Semaglutide acts on the GLP-1 receptor alone. Tirzepatide is an agonist of both the GLP-1 receptor and glucose-dependent insulinotropic polypeptide. Both drugs are associated with strong signals of CV benefit overall and in heart failure specifically, even if the evidence in HFpEF is 'stronger,' according to the statement. Incretin drugs mimic hormones that downregulate appetite. They are considered third-generation anti-obesity agents on the basis of their targeted mechanism and a low relative risk for adverse events. More than a dozen such agents are now in various stages of development, according to the ACC statement. Semaglutide and Tirzepatide Trials Differ In the STEP-HFpEF trial, which like SUMMIT trial, was placebo controlled, the 7.8-point gain ( P <.0001) in the KCCQ on active therapy vs placebo was statistically significant, as was the percent body weight loss (-13.3% vs -2.6%; P < .001). The SUMMIT trial found a 6.9-point gain in the KCCQ score ( P < .001) relative to placebo, while the rate the composite event endpoint of CV death from events associated with heart failure was lower (9.9% vs 15.3%; P = .026), but CV deaths occurred in only 13 patients. Heart failure events were observed in 81 patients over 2 years of follow-up. In both studies, significant gains in the secondary endpoints of physical and exercise function were associated with the assigned weight-loss drug. On the evidence so far, the authors of the ACC statement concluded that despite the marginal benefit observed in the SUMMIT trial, no firm conclusions can be made about the ability of incretin therapies to protect patients with HFpEF against hard endpoints, Kittleson said. Until more data are available, she cautioned against the risk for 'indication creep,' the willingness to offer these drugs for potential benefits that have yet to be confirmed. Still, she added, 'the goal of the writing group was to strike a tone of cautious optimism guided by the available data.' Part of this optimism has been fueled by the 2023 SELECT trial, which enrolled more than 17,000 patients with overweight with CV disease but no diabetes. Relative to placebo, semaglutide was associated with a 20% reduction ( P < .001) in the composite primary endpoint of CV death, nonfatal myocardial infarction, and nonfatal stroke. Only 24% of patients in this study had heart failure, but the risk reduction in this group was consistent with that of the study population as a whole. Obesity is listed in most guidelines, including a 2024 ACC Expert Consensus Decision Pathway for Treatment of HFrEF, as a common comorbidity of heart failure and potentially treatable risk factor for symptoms and progression of the condition. However, the new statement differs from prior guidelines. Typically, lifestyle modifications are identified as a first step toward weight loss. 'Patients should not be required to try and fail lifestyle changes prior to initiating pharmacotherapy,' according to Olivia Gilbert, MD, a cardiologist specializing in advanced heart failure and transplantation at Atrium Wake Forest Baptist Medical Center, in Wake Forest, North Carolina. Although Gilbert was not part of the writing committee for the new document, she has been involved in developing clinical guidance statements for the ACC. The incretin therapies are more effective than lifestyle medications and safer than procedure-based weight-loss interventions, Gilbert said, providing a basis for suggesting they can be considered first line therapy for patients with symptomatic HFpEF. 'Lifestyle interventions should always be offered in conjunction with obesity medications,' she said.
Globe and Mail
a day ago
- Business
- Globe and Mail
Anti‑Obesity Drugs Market to Reach USD 100.97 Billion by 2030, Driven by GLP‑1 Incretins and Uptake of Oral Treatments
Mordor Intelligence has published a new report on the Anti‑Obesity Drugs Market, offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction Mordor Intelligence, in its latest anti‑obesity drugs market report, forecasts the market to reach from USD 25.93 billion in 2025 to USD 100.97 billion by 2030, advancing at a 31.24 % CAGR. The anti-obesity drugs market focuses on medications developed to aid in weight loss and manage obesity related conditions. Obesity is a chronic, relapsing condition associated with several health issues, including type 2 diabetes, cardiovascular diseases, sleep apnea, and certain cancers. As global obesity rates rise driven by sedentary lifestyles, poor dietary habits, and genetic factors, there is growing demand for medical interventions beyond lifestyle changes and bariatric surgery. Key Trends The anti‑obesity drugs landscape is being reshaped by several important developments: 1. GLP‑1 receptor agonists gaining dominance Gut‑hormone incretins, primarily GLP‑1 agonists, are set to expand at 33.15 % CAGR through 2030. Their strong efficacy in reducing weight and favorable safety profiles have led major pharmaceutical companies to scale up production and secure lifecycle extensions for these agents 2. Oral formulations on the rise Although injectables account for 81.3 % of the 2024 market share, oral anti‑obesity drugs are projected to grow at an impressive 36.6 % CAGR through 2030. This surge reflects patient preference for pill-based therapies and investment in oral GLP‑1 pills by developers. 3. Prescription segment maintains leadership Prescription drugs commanded 84.2 % of the anti‑obesity drugs market in 2024. Over‑the‑counter options trail behind but are gaining traction, with the prescription category still growing at a 32.56 % CAGR through 2030 4. Digital pharmacies unlocking access Retail pharmacies held 54.05 % of the market in 2024, but online pharmacies are catching up. They are expected to grow at a 34.75 % CAGR, spurred by e‑commerce ease and expanding reimbursement support. 5. Asia‑Pacific emerging fast North America remains the largest market with a 65.9 % revenue share in 2024. However, Asia‑Pacific is advancing at a robust 33.65 % CAGR, driven by rising healthcare spending and expanding obesity awareness. Market Segmentation The anti‑obesity drugs market can be segmented in multiple ways, enabling stakeholders to identify growth pockets and tailor strategies. By Mechanism of Action Peripherally acting drugs led revenue in 2024, capturing 60.10% of the market. These medications act within the digestive system, such as fat‑absorption inhibitors and appetite suppressants, reducing energy uptake or signalling fullness. Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through 2030. These therapies mimic or enhance gut hormones to regulate appetite and blood sugar. Prescription drugs held a dominant share at 84.20% in 2024. This category includes clinically validated medications with regulatory backing and reimbursement frameworks. Over‑the‑counter (OTC) drugs occupy a smaller share but are gradually gaining influence through ease of access and increasing consumer trust. By Route of Administration Injectables commanded 81.30% of the market in 2024, driven by the widespread use of injectable GLP‑1 therapies known for their strong efficacy. Oral drugs are emerging as the most dynamic segment, projected to grow at a 36.60% CAGR from 2025 to 2030, reflecting a clear patient trend toward pills over injections. By Distribution Channel Retail pharmacies made up 54.05% of market revenues in 2024, remaining the standard way for patients to obtain anti‑obesity medications. Online pharmacies are fast growing (projected 34.75% CAGR to 2030), propelled by telehealth, convenient home delivery, and evolving reimbursement policies. By Geography North America was the largest regional market, securing a 65.90% share in 2024. This dominance stems from advanced healthcare systems, approval frameworks, and strong payer support. Asia‑Pacific is the fastest expanding region, with a projected CAGR of 33.65%. Growth drivers include rising obesity awareness, healthcare investments, and broader pharmaceutical access. Key Players Roche Roche is a global pharmaceutical company that has recently entered the anti-obesity drugs market. The company has secured licensing agreements for potential weight loss candidates, signaling its interest in expanding its portfolio to include obesity treatments. Roche's expertise in biotechnology and commitment to addressing unmet medical needs position it as a noteworthy participant in the obesity care landscape. GlaxoSmithKline (GSK) GSK is a multinational healthcare company involved in the development of various therapeutic areas, including obesity. The company is exploring the potential of amylin analogs and other hormonal agents for weight management. GSK's research initiatives aim to provide patients with alternative treatment options and contribute to the advancement of obesity care. Novo Nordisk Novo Nordisk is a leading global healthcare company specializing in diabetes and obesity care. The company has developed several GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy), which have shown significant efficacy in weight management. Novo Nordisk continues to invest in research and development to expand its portfolio of anti-obesity medications and enhance patient outcomes. Currax Pharmaceuticals Currax Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for obesity. Through strategic acquisitions, such as obtaining rights to Contrave, Currax has expanded its presence in the anti-obesity drugs market. The company's focus on addressing obesity-related health issues aligns with the growing demand for effective weight management therapies. Eli Lilly and Company Eli Lilly is another major player in the anti-obesity drugs market, known for its innovative therapies. The company's GLP-1 receptor agonist, tirzepatide (marketed as Mounjaro), has demonstrated promising results in clinical trials for weight loss. Eli Lilly's commitment to obesity care is reflected in its ongoing research efforts and strategic partnerships aimed at advancing treatment options for patients. Conclusion The anti‑obesity drugs market is entering a transformative era, with expected growth from USD 25.93 billion in 2025 to USD 100.97 billion by 2030 at a 31.24 % CAGR. This growth is fuelled by the powerful clinical outcomes of GLP‑1 agonists, innovation in oral formulations, expanded access via online pharmacies, and increasing attention to obesity as a chronic disease. While North America remains the dominant market, Asia‑Pacific's rapidly growing demand offers substantial opportunities. Competition is intensifying, as established pharmaceutical companies and biotechs alike race to advance next generation therapies and diversify distribution channels. As market dynamics evolve, stakeholders should monitor: • Progress of oral GLP‑1 candidates and dual/triple‑agonists like CagriSema • Regulatory approvals and reimbursement pathways, especially in emerging regions • Competitive responses from lifecycle extensions to partnerships and acquisitions • Supply chain robustness and accessibility, particularly amid supply constraints for high‑demand drugs In sum, the anti‑obesity drugs market is poised for significant expansion, with transformative treatments and shifting delivery models likely to reshape global healthcare delivery and patient outcomes. Industry Related Reports Ozempic Market : The Ozempic Market Report is segmented by region, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report provides both value (in USD) and volume (in units) for each of these segments. Japan Oral Anti-Diabetic Drug Market: The Japan Oral Anti-Diabetic Drug Market Report is segmented by drug types, including Biguanides, Alpha-Glucosidase Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, and others, as well as end users, such as Hospitals/Clinics, Personal/Home Care Settings, and others. The report provides market size and forecasts for each segment in terms of value (USD). Get More Insights: Anti-Snoring Market: The Anti-Snoring Devices Market report segments the industry by device type, including Mandibular Advancement Devices (MAD), Tongue Stabilizing Devices (TSD), Continuous Positive Airway Pressure (CPAP) Devices, and other device types. It also segments by surgical procedures such as Uvulopalatopharyngoplasty (UPPP), Somnoplasty, Pillar Procedure, Tonsillectomy, Radiofrequency Palatoplasty, and more. Additionally, the report covers geographical segmentation. About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@
